Toku is a health technology company developing AI-powered solutions that analyze retinal images to detect systemic diseases, including cardiovascular conditions. The company’s proprietary platform, CLAiR, enables non-invasive, rapid, and scalable health screening by turning the eye into a window to overall health.
Founded by experts in ophthalmology, biomedical engineering, and artificial intelligence, Toku aims to revolutionize preventative care by using the retina as a biomarker for cardiovascular and other systemic diseases. Its technology integrates seamlessly into existing retinal imaging workflows and provides real-time, clinically relevant health insights from a standard eye exam.
With a strong focus on early detection, clinical validation, and ease of deployment, Toku is transforming how cardiovascular risk and other health issues are identified—starting with a simple eye scan.
Features
AI-Driven Retinal Image Analysis: Toku’s core platform, CLAiR, uses artificial intelligence to analyze high-resolution retinal images and detect markers associated with cardiovascular and systemic disease risk.
Non-Invasive and Rapid: The system requires only a standard retinal photo—no blood draw, radiation, or invasive test—to deliver insights within minutes.
Cardiovascular Risk Detection: CLAiR identifies signs related to heart attack, stroke, and other cardiovascular conditions, helping enable earlier intervention and preventive care.
Seamless Workflow Integration: Toku’s platform is designed to work with existing fundus cameras and imaging systems, allowing for easy implementation in clinical practices and vision centers.
Clinically Validated Algorithms: The AI has been trained and validated using diverse datasets to ensure performance across different populations and image acquisition settings.
Point-of-Care Insights: The solution provides real-time analysis that can be delivered directly at the point of care, supporting immediate decision-making by healthcare providers.
Scalable for Population Health: Toku’s technology supports high-volume screenings, making it suitable for public health programs and chronic disease monitoring initiatives.
HIPAA-Compliant and Secure: The platform is built with patient data security in mind and complies with privacy regulations, including HIPAA.
How It Works
Toku’s platform begins with the acquisition of a standard retinal image using a digital fundus camera. This non-invasive image is then uploaded to Toku’s secure platform, where the CLAiR algorithm analyzes it using machine learning models.
Within minutes, the system identifies specific features in the retinal vasculature that are scientifically linked to systemic health indicators, such as arterial stiffness or microvascular abnormalities—both of which can reflect cardiovascular risk.
The AI then generates a health report that indicates the patient’s relative risk of cardiovascular events. This report can be integrated into the clinical workflow or delivered to the patient via the healthcare provider for further consultation or referral.
Because the retina offers a unique view of microvascular health, Toku’s system is able to extract a wide range of health signals without the need for any invasive diagnostics or laboratory processing.
Use Cases
Toku is designed for healthcare environments where early detection and prevention of chronic disease are essential.
In primary care and cardiology clinics, the platform can be used as a frontline screening tool to assess cardiovascular risk and prioritize patients for further evaluation.
In optometry and ophthalmology practices, Toku enables eye care professionals to play a proactive role in whole-body health by identifying patients who may be at risk for cardiovascular conditions, even when visiting for vision care.
In public health initiatives and screenings, especially in underserved or remote areas, Toku can scale rapidly to assess large populations for systemic health risks using widely available retinal imaging equipment.
Employers and wellness programs can integrate Toku into preventative health screenings as a non-invasive, quick way to offer health risk assessments to employees.
Researchers and health systems use Toku to collect population-level data on retinal biomarkers associated with chronic disease, supporting better outcomes through early intervention strategies.
Pricing
Toku does not publicly disclose pricing on its website. The platform is offered as a B2B solution, with pricing tailored to the specific needs of clinics, healthcare systems, optometry networks, or research institutions.
Costs likely depend on the number of screenings, integration requirements, and volume of usage. Interested organizations are encouraged to contact Toku directly for a customized demo and pricing proposal.
Toku may also offer flexible pricing or pilot programs for health systems interested in evaluating the technology before full-scale deployment.
Strengths
Toku’s primary strength is its ability to extract rich health insights from a single retinal image, eliminating the need for invasive procedures or lab tests.
The platform is non-disruptive and easily deployable, using existing imaging equipment in optometry and primary care settings.
Its focus on cardiovascular disease detection positions it to make a meaningful impact in early diagnosis and prevention, addressing a leading cause of global mortality.
The use of AI for real-time analysis improves clinical efficiency and enables providers to deliver more proactive care based on objective data.
Toku’s system is also well-suited for large-scale screenings, including in low-resource settings, due to its scalability and non-reliance on physical samples or bloodwork.
Its commitment to clinical validation and compliance with data security standards enhances trust in the platform from both healthcare providers and patients.
Drawbacks
While Toku offers groundbreaking potential, it is focused primarily on cardiovascular risk detection, which may limit its scope for providers looking for broader diagnostic capabilities.
Its reliance on high-quality retinal images means that poor image acquisition can affect the accuracy of results, requiring proper training and camera standards.
The technology is currently positioned for enterprise or clinical adoption and is not yet available for direct consumer use, limiting accessibility for individuals.
Toku’s platform is relatively new in a rapidly evolving space, and ongoing validation and peer-reviewed evidence will be important to support broader adoption.
The absence of transparent pricing may create barriers for smaller clinics or independent practices evaluating the platform.
Comparison with Other Tools
Toku can be compared to other health AI platforms leveraging retinal imaging, such as Eyenuk, IDx, and Google’s DeepMind health initiatives.
Eyenuk’s EyeArt platform focuses on diabetic retinopathy detection, while IDx is FDA-approved for autonomous detection of diabetic eye disease. Both focus on ocular conditions.
Google’s DeepMind has developed algorithms that detect systemic conditions like anemia from retinal images, but these are largely in research stages and not yet commercially available.
Toku stands apart by using retinal data not just to detect eye disease, but to identify broader systemic conditions like cardiovascular risk. This makes it a more comprehensive preventive tool for general health, rather than one limited to vision care.
Its seamless integration into standard retinal imaging workflows also differentiates it as a scalable, practical solution for both eye care and primary care environments.
Customer Reviews and Testimonials
Toku’s website does not currently feature public customer reviews or testimonials. However, the company emphasizes ongoing clinical research and collaboration with healthcare providers and public health organizations.
Toku is actively partnering with institutions and vision care networks to validate its AI models and deploy its platform in real-world settings.
The company has been featured in healthcare innovation publications and is gaining attention for its potential to change how systemic health is assessed through non-invasive imaging.
Organizations interested in learning more are encouraged to contact Toku for access to pilot results, case studies, or clinical validation data.
Conclusion
Toku is a pioneering health AI company transforming retinal imaging into a powerful tool for systemic health screening. With its CLAiR platform, healthcare providers can detect early signs of cardiovascular risk using a fast, non-invasive retinal photo—enhancing preventative care and improving health outcomes.
Its seamless integration, focus on validated biomarkers, and scalable design make Toku a strong solution for clinicians, health systems, and public health initiatives seeking to improve early detection and disease prevention.
By turning routine eye exams into a gateway for whole-body health insights, Toku is helping shape the future of predictive healthcare.
